NEW YORK (GenomeWeb News) – Protein analytics firm BioScale said in a regulatory document that it has raised $18.8 million of a targeted $38.3 million financing round.

The Lexington, Mass.-based firm disclosed the raise in a document filed on Monday with the US Securities and Exchange Commission, saying the securities offered were in the form of equity. It did not disclose the names of the investors but said 69 investors have invested in the offering. It did not say how proceeds from the raise would be used.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.